Variant Neurodegenerative Proteins With Reduced Seed Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy for neurodegenerative diseases, such as Alzheimer's and Parkinson's, is costly and ineffective in stopping disease progression once nerve cell death occurs, with passive antibody therapy being expensive and active vaccine therapy having limited brain penetration and efficacy.
Innovation Solution
Development of variant neurodegenerative disease-associated proteins with reduced seed activity, achieved through amino acid deletions, substitutions, or additions in the protofilament interaction regions of proteins like alpha-synuclein, tau, and amyloid beta, which function as nuclei for protein aggregates, potentially serving as safer and more effective vaccines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If passive immunotherapy with monoclonal antibodies is used, then treatment effectiveness is improved, but treatment cost increases significantly
Solution Approach 1:
The patent creates a simplified copy of the therapeutic mechanism by using recombinant antibody fragments (scFv, Fab) instead of full-length monoclonal antibodies. These fragments retain the essential antigen-binding capability while being smaller, easier to produce, and less expensive to manufacture, thus resolving the contradiction between effectiveness and cost.
Solution Approach 2:
The patent segments the monoclonal antibody into functional domains by using only the variable regions (VH and VL) that bind to the antigen. This segmentation eliminates the need to produce and administer the entire antibody molecule, reducing manufacturing complexity and cost while preserving the therapeutic effect through the retained binding function.
2Ease of manufacture
If active immunotherapy with vaccines is used, then treatment cost is reduced, but brain penetration and efficacy are limited
Solution Approach 1:
The patent uses recombinant antibody fragments as intermediaries that bridge the advantages of both passive and active immunotherapy. These fragments can be produced at vaccine-like costs but possess proven therapeutic efficacy from antibody therapy, serving as a mediator that transfers the beneficial properties of both approaches.
Solution Approach 2:
The patent changes the physical and functional parameters of the antibody by using truncated versions with reduced molecular weight. This parameter change improves pharmacokinetic properties including potential brain penetration while maintaining antigen-binding affinity, thus resolving the contradiction between cost and efficacy.
3Reliability
If antibody therapy is administered after disease onset, then aggregated proteins are removed from the brain, but cognitive function improvement is limited
Solution Approach 1:
The patent enables preliminary action by allowing treatment to be administered at earlier disease stages including preclinical and prodromal phases. The use of cost-effective recombinant antibody fragments makes long-term early intervention feasible, preventing disease progression before significant neuronal damage occurs, thus improving cognitive outcomes.
Solution Approach 2:
The patent facilitates self-service by enabling treatment to begin in the preclinical stage when patients are asymptomatic. Early intervention allows the therapeutic agent to work preventively, reducing the burden of disease before it manifests clinically, thereby improving long-term cognitive function through proactive rather than reactive treatment.
Data Source
AI summary
A variant neurodegenerative disease-associated protein, which comprises an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids present in the interaction region of two molecules of protofilaments (PF) in the amino acid sequence of a neurodegenerative disease-associated protein, and in which seed activity that functions as a nucleus of an aggregate of the neurodegenerative disease-associated protein is reduced.